MAIA Biotech gets FDA Fast Track for ateganosine in NSCLC; Phase 2 data shows 17.8-month median OS

MAIA Biotechnology, Inc.

FDA granted Fast Track designation for ateganosine (THIO) for treatment of non-small cell lung cancer.
Phase 2 THIO-101 trial showed median overall survival of 17.8 months in heavily pre-treated patients, vs. 5-6 months for standard of care.
Ateganosine is a first-in-class small molecule telomere-targeting agent; if approved, could compete in $34B NSCLC market.
Fast Track enables accelerated approval and priority review; FDA decision possible as early as next year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.